tiprankstipranks
Advertisement
Advertisement

KURA Stock Latest News

Kura Oncology Enhances Executive Severance, Change-in-Control Terms
Company AnnouncementsKura Oncology Enhances Executive Severance, Change-in-Control Terms
7d ago
8K
KURA
Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data
PremiumRatings
Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data
10d ago
KURA
Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC
PremiumRatings
Analyst Maintains Buy Rating and Unchanged $40 Price Target on Encouraging Darlifarnib Combination Data in Advanced RCC
10d ago
KURA
Kura Oncology announces durable activity of darlifarnib combination in ccRCC
PremiumThe Fly
Kura Oncology announces durable activity of darlifarnib combination in ccRCC
10d ago
KURA
Zhu Reiterates Buy on Ziftomenib Developer, Citing Strong Phase 1 AML Data and Favorable Safety Profile; Price Target Maintained at $28
PremiumRatings
Zhu Reiterates Buy on Ziftomenib Developer, Citing Strong Phase 1 AML Data and Favorable Safety Profile; Price Target Maintained at $28
2M ago
KURA
Syndax price target lowered to $31 from $34 at Guggenheim
PremiumThe FlySyndax price target lowered to $31 from $34 at Guggenheim
2M ago
KURA
SNDX
Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer
Premium
Company Announcements
Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer
2M ago
KURA
Kura Oncology Shareholders Approve Expanded Equity Incentive Plans
Premium
Company Announcements
Kura Oncology Shareholders Approve Expanded Equity Incentive Plans
2M ago
8K
KURA
Analyst Reiterates Buy on Kura Oncology, Maintains $40 Price Target on Expanding Darlifarnib Combination Platform
PremiumRatings
Analyst Reiterates Buy on Kura Oncology, Maintains $40 Price Target on Expanding Darlifarnib Combination Platform
2M ago
KURA
Kura reports data supporting darlifarnib potential for KRAS-mutant cancers
PremiumThe Fly
Kura reports data supporting darlifarnib potential for KRAS-mutant cancers
2M ago
KURA
Kura Oncology reports first-in-human data from the FIT-001 clinical trial
PremiumThe Fly
Kura Oncology reports first-in-human data from the FIT-001 clinical trial
2M ago
KURA
Kura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
PremiumRatings
Kura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
3M ago
KURA
Kura Oncology Earnings Call Signals Early Launch Strength
PremiumCompany AnnouncementsKura Oncology Earnings Call Signals Early Launch Strength
3M ago
KURA
Kura Oncology Earnings Call Highlights Comzifty Momentum
Premium
Company Announcements
Kura Oncology Earnings Call Highlights Comzifty Momentum
3M ago
KURA
Closing Bell Movers: Karman falls over 10% after Q1 earnings miss
Premium
The Fly
Closing Bell Movers: Karman falls over 10% after Q1 earnings miss
3M ago
AIP
INR
Kura Oncology reports Q1 EPS (83c), consensus (78c)
PremiumThe Fly
Kura Oncology reports Q1 EPS (83c), consensus (78c)
3M ago
KURA
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
PremiumThe Fly
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
3M ago
KURA
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
PremiumRatings
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
4M ago
KURA
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
PremiumRatings
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
4M ago
KURA
Kura Oncology reports results from ongoing FIT-001 clinical trial
PremiumThe FlyKura Oncology reports results from ongoing FIT-001 clinical trial
4M ago
KURA
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
4M ago
ANGX
IMRX
Kura Oncology initiated with a Buy at Lake Street
Premium
The Fly
Kura Oncology initiated with a Buy at Lake Street
4M ago
KURA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >